Lupin bets Biosimilars to cross $100 Mn scale in 3 years; plans in-licensing to innovate India biz

The Mumbai-based drugmaker expects its new biosimilar launches to generate over $100 million in sales over the next three years, while its 505(b)(2) portfolio is expected to offset the anticipated moderation in US sales. In India, the company has outlined an ambitious 10-year roadmap to transform its portfolio, with innovative medicines targeted to account for 30 per cent of the product mix, driven by in-house R&D and licensing push.